Comprehensive analysis of BUBs gene family in lung adenocarcinoma with immunological analysis

Abstract

Lung adenocarcinoma (LUAD) is one of the most commonly malignant tumors, and major challenges remain in the treatment of LUAD. Budding uninhibited by benzimidazole 1/3 (BUB1/3) play significant roles in the process of spindle-assembly checkpoint (SAC) during mitosis. However, their roles in LUAD have not been established. Here, we performed an immunological analysis of BUB1/3 in LUAD using a comprehensive bioinformatics approach, quantitative real-time-PCR and Western blotting technique. Our results indicated that the expression levels of BUB1 and BUB3 in LUAD samples were higher than the expression levels in the control groups and were associated with some clinicopathologic parameters in patients with LUAD. BUB1/3 and their related genes were enriched in cell immune, and the immune infiltration analysis revealed that the BUB1/3 expression profile was significantly correlated with characteristics of immune cell infiltration. Survival analysis showed that the diseasefree survival and overall survival of patients with LUAD decreased with an increase in the BUB1/3 expression levels. The mRNA and protein expression levels of BUB1 and BUB3 in each of the LUAD cell lines were upregulated to varying degrees. BUB1 and BUB3 are the potential immunological therapeutic intervention targets for patients with LUAD.

BUB1 inhibition sensitizes lung cancer cell lines to radiotherapy and chemoradiotherapy

“…further emphasizes its significance in lung cancer. No correlation between BUB1 expression and cancer stage or grade was observed (Figures 1J-K), consistent with findings in other cancers including LUAD (12,24).…”

“…Confirmation of BUB1 overexpression in tumor tissues ( Figures 1H-I and 1L ) and lung cancer cell lines ( Figure 1M ) further emphasizes its significance in lung cancer. No correlation between BUB1 expression and cancer stage or grade was observed ( Figures 1J-K ), consistent with findings in other cancers including LUAD (12, 24).…”

UBE2C: A pan‐cancer diagnostic and prognostic biomarker revealed through bioinformatics analysis

“…Significantly increased UBE2C expression level in various tumor types, including CESC, CHOL, GBM, and UCS tumors (with AUC = 100%) or in ACC, BLCA, BRCA, COAD, ESCA, KICH, KIRC, KIRP, LGG, LIHC, LUAD, LUSC, OV, PAAD, READ, SKCM, STAD, TGCT, and UCEC tumors (with AUC ≥90%) suggest that assessing UBE2C gene expression could serve as a novel biomarker for tumor staging and a promising diagnostic tool prior to symptoms manifestation. The diagnostic value of UBE2C has been previously reported in patients with hepatocellular carcinoma (HCC) and liver cancer 42,43 . Consistently, a recent study reported that detecting of UBE2C expression level through IHC sections could be an indicator of polyploidy in cancer tissue, allowing discrimination of aggressive subsets of HCC.…”